An overview of Ecuador’s 2026 mining reform, focusing on regulatory changes, investment risks, and key considerations for structuring mining projects under the new framework.

Find out why our firm is the go-to legal advisor for businesses operating in Ecuador's most complex and regulated industries.

We secured a landmark cassation ruling on unfair competition and unlawful pharmaceutical advertising, setting a key precedent for market transparency in Ecuador.

Meythaler & Zambrano achieved a key judicial victory overturning an arbitrary drug price cap, reinforcing due process and transparency in pharmaceutical regulation.

We successfully preserved a high-value family estate through judicial recognition of a post-mortem de facto union, thereby establishing a precedent in the field of succession law.

We achieved a second favourable SENADI resolution that strengthens test data exclusivity in Ecuador’s pharmaceutical sector.

Ecuadorian suppliers are under investigation for alleged money laundering and the use of offshore companies to hold assets within U.S. territory.

Ecuador’s IP law analyzed by Meythaler & Zambrano in Legal 500’s 2025 guide on trademarks, patents, and enforcement.

Ecuador’s 2025 Manual sets new rules for planning and procuring medicines and medical devices in the public health system.

Recognized in Chambers Latin America 2026 for Tax, Dispute Resolution, and Intellectual Property in Ecuador.

Meythaler & Zambrano secured the first SENADI ruling in Ecuador. This precedent strengthens IP rights in regulated industries such as pharma, agrochemicals, and biotech.

The Ecuador chapter, authored by Meythaler & Zambrano, offers practical guidance for pharmaceutical companies, insurers, and healthcare providers on regulation, pricing, public procurement, and digital health.